Table 1. TLR9 agonist induces the proliferation of TLR9-expression splenocytes in mice bearing an ectopic 3LL footpad tumor.
| Treatment | Spleen Weight (g) | Percentage in total splenoctyes (%) | ||||
| B cells | pDCs | NKDCs | CD3+CD4+ | CD3+CD8+ | ||
| NT | 0.12±0.01 | 53.6±3.2 | 1.1±0.1 | 2.2±0.4 | 22.2±3.8 | 14.9±2.1 |
| Control oligo | 0.10±0.04 | 55.5±3.6 | 1.6±0.5 | 2.7±1.1 | 22.2±2.8 | 15.7±2.8 |
| TLR9 agonist | 0.46±0.04(***)1 | 71.7±8.8(***) | 2.7±0.9(***) | 3.7±0.8(*) | 10.0±2.9(***) | 6.9±1.5(***) |
| RT | 0.30±0.04(***) | 54.6±4.2 | 1.0±0.2 | 2.5±0.7 | 19.8±3.9 | 14.3±1.9 |
| RT+TLR9 agonist | 0.46±0.04(***) | 72.9±3.0(**) | 3.0±0.5(**) | 5.0±0.7(**) | 10.1±2.5(**) | 6.5±1.7(***) |
1
Significant different when compared with NT (No Treatment) group; p values are expressed as “***” (p<0.001); “**” (p<0.01) and “*” (p<0.05).